Purine nucleoside antimetabolites in development for the treatment of cancer

Area of Science:

• Oncology
• Pharmacology

Background:

• Purine nucleoside analogs represent a significant class of anticancer therapeutics.
• Several purine analogs are FDA-approved, with more compounds undergoing clinical evaluation.
• Gene therapy approaches utilizing these analogs for targeted tumor cell activation are also under investigation.

Purpose of the Study:

• To review the current landscape and future potential of purine nucleoside analogs in cancer treatment.

Main Methods:

• Literature review of FDA-approved and clinically evaluated purine nucleoside analogs.
• Examination of gene therapy strategies involving purine nucleoside analogs.

Main Results:

• Five purine analogs are FDA-approved: mercaptopurine, thioguanine, fludarabine monophosphate, deoxycoformycin, and cladribine.
• Four additional compounds (clofarabine, immucillin-H, nelarabine, 8-chloroadenosine) are in clinical trials.
• Two gene therapy approaches are being evaluated for selective activation in tumor cells.

Conclusions:

• Despite extensive research over 50 years, purine nucleoside analogs remain a promising area for novel anticancer drug discovery.
• The continued development of new analogs and therapeutic strategies underscores their ongoing importance in oncology.